Update in rare and common causes of kidney stones
|
|
- Edmund Booth
- 5 years ago
- Views:
Transcription
1 Update in rare and common causes of kidney stones John C. Lieske, MD, FACP, FASN SECOND INTERNATIONAL RENAL CONFERENCE BRUGGE 2018 March 16-17, MFMER slide-1
2 Nephrologists and kidney stones Kidneys are cool (but complicated) Only nephrologists really understand how they work Kidney stones are made in the kidneys and are also complicated Even today the pathogenesis is poorly defined, but clearly the renal physiology we are so familiar with is very important Thus, this area of great unmet need is uniquely suited for our specialty 2017 MFMER slide-2
3 Outline Common urine stones Urine chemistries and stone risk Influence of sex Influence of genetics Influence of environment Rarer stone types Diagnosis Treatment 2017 MFMER slide-3
4 All stones submitted to Mayo Medical Labs in 2010 (n=48,446) Number Percent Majority Calcium oxalate 29, % Majority Apatite % Uric Acid % Struvite % Artifact % Brushite % Other % Cystine % Ammonium urate % Drug % Rare 1 } 83.4% Ca 2017 MFMER slide-4
5 Stone type varies by age and sex 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Male Age group 80% 70% 60% 50% 40% 30% 20% 10% 0% Female Age group Uric Acid Apatite Brushite Struvite Cystine Sodium/Potassium Urate Other Artifact Drug Ammonium Urate Calcium Oxalate 2017 MFMER slide-5
6 How do Kidney Stones Form?
7 Supersaturation RSS <1 1 >1 * DG <0 0 >0 * EQUIL2: computer simulation of supersaturation for calcium oxalate, uric acid, calcium phosphate 2017 MFMER slide-7
8 Why do kidney stones form? Urine is supersaturated Some people more than others Most likely other factors But (in 2018) the supersaturation is what we can fix SS correlates with stone type and risk of recurrence Therefore, our job is to figure out: What is causing it and how best to fix it! 2017 MFMER slide-8
9 Key Risk Factors for idiopathic calcium oxalate stones directly related to urinary supersaturation 1. Low volume/ concentrated urine 2. Hypercalciuria 3. Hypocitraturia 4. Hyperoxaluria 5. Hyperuricosuria
10 Drinking water works! Parameter a Placebo Tolvaptan P* (n= 20) (n= 19 ) Serum Na (meq/l) 141±2 142± Serum K (meq/l) 4.1± ± Serum Cl (meq/l) 102±3 102± Serum Bicarb (meq/l) 28±3 27± Serum BUN (mg/dl) 15±4 14± Serum Cr (mg/dl) 0.9± ± Urine volume (ml/24h) 1833± ±2866 <0.001 Urine ph 6.3± ± Osmolarity, mosm/kg 529± ±96 <0.001 Ammonia (mmol/24h) 33±38 26± Calcium (mg/24h) 148± ± Chloride (mmol/24h) 108±72 91± Citrate (mg/24h) 413± ± Creatinine (mg/24h) 1096± ± Magnesium (mg/spec) 76±53 87± Oxalate (mg/24h) 15±8 23± Phosphate (mg/24h) 714± ± Potassium (mmol/24h) 46±46 51± Sodium (mmol/24h) 111±56 97± Uric acid (mg/24h) 473± ± Calcium oxalate SS (DG) 0.95± ±1.14 <0.001 Calcium phosphate (BR) SS (DG) -0.13± ±1.17 <0.001 Uric acid SS (DG) -2.05± ±
11 Drinking water works! Urine Volume 1.81 L 1.83 L 4.81 L Baseline Placebo Tolvaptan Urinary SS (DG) CaOx CaP (BR) UA
12 Thirst and urine flow differs by age and sex
13 Heritabilities of urinary traits Lieske et al: CJASN 2014
14 Systematic differences in calcium metabolism amongst first time stone formers
15 Systematic differences in calcium metabolism amongst first time stone : subtle shift in 1,25 vitamin D levels* Number of pe ersons 1,25 vitamin D 90% calcium oxalate *and serum calcium, PTH, and FGF 23
16 Variable effect of age on urine calcium and other stone risk factors
17 Idiopathic Hypercalciuria Genetic Hypercalciuria Familial: 50% of 1 st degree relatives affected On average, behave functionally as if in a state of vitamin D excess (increased dietary absorption) Renal reabsorption further influenced by diet (Na, protein, sucrose) Low bone mineral density Genetics likely to be complex.. Monogenic causes Bartter s syndrome Dents Soluble adenyl cyclase Ca sensing receptor Claudin 14 CYP24A1 (abnormal 24 vitamin D hyroxylation)
18 Heritabilities of dietary traits! Lieske et al: CJASN 2014
19 Case 1 50 yo gentleman 2 stones Removed ureteroscopically age 30 Removed percutaneously age 36 Neither analyzed Noted to have reduced GFR at age 30 (egfr ~40-50 ml/min/1.73 m 2 ) At a check-up age 49 had fallen to ~30 ml/min/1.73 m 2 Started on low sodium/low protein diet egfr trickled down to 20 s over the next months 2017 MFMER slide-19
20 Case 1 In early 2014 hospitalized with pneumonia Developed acute on chronic kidney injury A kidney biopsy revealed crystal deposition and an acute inflammatory reaction Peritoneal dialysis initiated soon thereafter No family history of kidney disease or stones (two siblings and twin sons) On exam he looks fit 2017 MFMER slide-20
21 Some test results 2017 MFMER slide-21
22 Some test results Plasma oxalate 23.2 µmol/l Urine oxalate 11 mg (Creatinine 447 mg) 1991 urine oxalate 42 mg U/A ph 7.0; trace protein 2017 MFMER slide-22
23 Urine microscopy 2017 MFMER slide-23
24 A DHA: Dihydroxyadenine B C D E COD * COM Cystine Calcium Oxalate Calcium Phosphate 2017 MFMER slide-24
25 Renal Biopsy Not everything that polarizes is calcium oxalate! 2017 MFMER slide-25
26 These are characteristic DHA crystals Confirmatory enzymatic testing on blood spot (UCSD) 2017 MFMER slide-26
27 Other confirmatory testing (research basis) APRT Genetic testing Urine DHA quantification Landspitali University Hospital Reykjavik Iceland 2017 MFMER slide-27
28 X Adenine APRT AMP IMP XDH Adenosine Inosine HPRT 2,8-Dihydroxyadenine Hypoxanthine XDH Xanthine XDH Uric acid Edvardsson et al, Pediatr Nephrol, 2013;28(10): MFMER slide-28
29 The APRT gene Located on chromosome 16q24 Approximately 50 pathogenic human APRT mutations reported all completely abolish enzyme function No genotype-phenotype correlations have been identified MFMER slide-29
30 Treatment Allopurinol? Febuxostat Kidney transplant No liver transplant! 2017 MFMER slide-30
31 Epidemiology The disorder described in all ethnic groups and the majority of reported cases have come from Japan, France, and Iceland. Estimated heterozygote frequency approximately 1% (1.25% in Iceland, whole genome sequencing data). 35 known cases in Iceland (prevalence,1:10,000); Calculated number = 52 based on gene frequency Less than 400 cases reported world wide. Lack of awareness is likely contributing to the low number of reported cases worldwide 2017 MFMER slide-31
32 Monitoring effectiveness of pharmacotherapy Current practice Absence of urinary DHA crystals has been considered indicative of adequate therapy. This approach has proven inadequate and a more reliable method to guide treatment is needed. Future A UPLC-MS/MS assay for the measurement of urinary DHA excretion, as a tool for therapeutic drug monitoring. Although we believe the UPLC-MS/MS assay will greatly enhance treatment monitoring, additional studies are needed MFMER slide-32
33 Results Clinical Drug Trial The median (range) 24 hr urinary DHA excretion was: 256 ( ) mg off drug therapy. 85 (7 236) mg on allopurinol treatment. 0.2 ( ) mg on febuxostat treatment MFMER slide-33
34 Case 2 55 yr old female, native of India Multiple stones onset in mid 20s; 3 SWL+ 1 ureteroscopy; passed 3-4 others; most recent in 2013 Brother died at age 10 with kidney stones and kidney failure Parents both had one kidney stone each but no other kidney failure in family 2017 MFMER slide-34
35 Case 2 cont d Creatinine was 0.8 and 0.7 in 2014 and 2015 Bump in May 2017 to 1.6 and in June to It was 2.5 in the middle of October and more recently 2.6. She had a kidney biopsy in early October 2017 which showed evidence of oxalate crystal deposition. She has had some issues with dehydration and an episode of SVT that required a hospitalization recently. BTW use of herbal remedies 2017 MFMER slide-35
36 Case MFMER slide-36
37 Case MFMER slide-37
38 Case MFMER slide-38
39 Case 2 cont d Genetic testing for AGXT performed in the RKSC research lab. Homozygous c.568g>a change Type 1 Primary Hyperoxaluria 2017 MFMER slide-39
40 Primary Hyperoxaluria 2017 MFMER slide-40
41 Primary Hyperoxaluria: Hepatic pathways PH1 (74%): AGT PH2 (8%): GRHPR PH3 (8%): HOGA LDH OXALATE LDH OXALATE PH 1 and PH2: Cytosolic LDH: Glyoxalate Oxalate (-) PH3:?? Ancillary tests PH1: Glycolate PH2: Glycerate PH3: 4-hydroxyglutamate 2017 MFMER slide-41
42 Urine oxalate is a key risk factor for ESRD in PH Zhao et al Clin J Am Soc Nephrol 11: , MFMER slide-42
43 Renal failure is common especially in PH1 Zhao et al Clin J Am Soc Nephrol 11: , MFMER slide-43
44 Proximal tubule CaOx RSS PT Ox = (UOx*V)/(GFR*(1-r)) PTCaOx RSS = (UFCa * PT Ox)/ 40 Worcester et al: A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in PH1. AJP 305: MFMER slide-44
45 Urine Proximal Tubular CaOx RSS by patient type 2017 MFMER slide-45
46 Relationship between plasma oxalate and egfr in PH, EH and USD patients Perinpam M, et al. Clin Biochem. 50(18): , MFMER slide-46
47 Glycolate Oxidase (GO) Knockdown with sirna to Starve Substrate for Oxalate Synthesis in PH1 Liebow et al: JASN 28: MFMER slide-47
48 2017 MFMER slide-48
49 Case 3 56 yr old gentleman Status post bilateral percutaneous nephrolithotomy age 36 Chronic kidney disease and hypertension with a baseline creatinine of 1.6 mg/dl Acute rise of creatinine to 2.6 mg/dl CT scan revealed very large stone burden in both kidneys. DMSA scan revealed 10% function in the right kidney and 90% in the left. The patient was however asymptomatic MFMER slide-49
50 Case 3 cont d Left PCNL with a secondary left PCNL on March 21, and a tertiary ureteroscopy over 10 d period. Removed stones were 100% cystine. The patient tolerated these procedures well. The left collecting system was completely devoid of stone at the end of these procedures. Postop CT still reveals stone material within most papillae on the left. The right atrophic kidney remains filled with a staghorn MFMER slide-50
51 Case 3- pre op 2017 MFMER slide-51
52 Case 3 post op 2017 MFMER slide-52
53 Case 3 5 mos later a procedure on the right to save function ; largely not successful Cr fluctuates mg/dl BP as high as 200 systolic; worsening LE swelling improved when Cardia, lisinopril, furosemide titrated up Albumin creat ratio (ACR) 2523 mg/g Before the initial procedure predicted 24 hr protein mg/day 2017 MFMER slide-53
54 Case 3 Kidney biopsy: Focal global sclerosis and mild arteriosclerosis Medical management continued Most recent visit 6 mos later BP 132/81 ACR 426 mg/g Cr 2.3 (but CysC 1.44 mg/l, egfr 49 ml/min/1.73m 2 ) 2017 MFMER slide-54
55 Cystinuria 2017 MFMER slide-55
56 Glomerular Capillary Cystine Apical Membrane + - Cystinuria Basolateral Membrane Cystine (and dibasic amino acids) SLC7A9 (b 0,+ AT) SLC3A1 (rbat) Cystine 2 Cysteine Blood URINE: should contain 0.4% of filtered cystine Cystinuria: contains 100% or more of filtered cystine 2017 MFMER slide-56
57 Cystinuria: The Problem Cystine is poorly soluble in urine Precipitates into crystals Crystals grow into stones One year 2017 MFMER slide-57
58 ICF Facebook Page: Highlights in Patient Viewpoint The doctors here are just so mis-informed and keep pushing me to do things that I know and are proven to NOT work but they never want to listen. HEY A- HOLE, LITHOTRIPSY DOES NOT WORK!!!!! In desperate need of some help. Anyone else suffer a mental break down due to this disease? Kaitlin tried to OD on Narco two weeks ago. Had to have her stomach pumped and was in ICU for three days. There's a 5mm stone heading south and taking prisoners on the way down. Dr. doubled my Delaudid prescription 2017 MFMER slide-58
59 Cystinuria causes worse health-related quality of life (HRQoL) than non-cystine stones Frank Modersitzki, MPH, Laura T Pizzi, PharmD, MPH, David S Goldfarb, MD Urolithiasis. 42:53-60, 2014 Improving HRQoL Domains with Time Since Last Stone 2017 MFMER slide-59
60 The only consequence is cystine stones, because cystine is poorly soluble Treatment of cystine stones Quantitate 24-hour cystine excretion Maintain water diuresis Maintain water diuresis low salt diet Low protein (methionine) diet Alkalinize urine d-penicillamine; thiola 2017 MFMER slide-60
61 Cystine excretion: Direct relationship to Na Goldfarb et al: KI 69: , MFMER slide-61
62 Case 3 Cystine MW 240 g/m 24 excretion = 533 mg Theoretic solubility 250 mg/l 2017 MFMER slide-62
63 Drug treatments for Cystinuria 2017 MFMER slide-63
64 Tiopronin Pak et al: J Urol 136: , MFMER slide-64
65 Cystine Solid Phase Assay: Cystine Supersaturation and Capacity Undersaturated Urine Add Cystine A measured amount of cystine crystals are incubated in stirred urine samples for 48 hours. Courtesy, John Asplin, Litholink Corp, Chicago IL Supersaturated 2017 MFMER slide-65
66 Study to determine tiopronin (CBTD) dose effect 1- People with cystinuria treated with tiopronin 2- Each subject takes part in 4 study periods (randomized): (1) CBTD at 0 g/d x 7 days (2) CBTD at 1 g/d (3) CBTD at 2 g/d (4) CBTD at 3 g/d (all BID dosing) 3-24-hour urine collection performed on Day 7 of each period 4- Mean cystine capacity of urine at each dose of CBTD is compared 2017 MFMER slide-66
67 Effect of CBTD Dose on CysCap N=8 P values MFMER slide-67
68 Importance of Treatment Adherence Without adherence to medical management, stone recurrence rates post-surgery are 45% at 3 months With adherence medical management, stone recurrence rates drop to 25% at 36 months Adherent patients (11/20) underwent significantly fewer surgical procedures per year vs. noncompliant patients (9/20) [1.0/patient vs. 4.0/patient, respectively (p<0.05)] 73% of the adherent patients were stone-free vs. 33% of the non-adherent group Byiani, CS, et al. Journal of Urology (2005): MFMER slide-68
69 Loss of GFR in cystinuria: still above that expected 2017 MFMER slide-69
70 JASN 2014
71 The future? RKSC 90+ gene panel Known and candidate monogenic causes
72 Call for questions MFMER slide-72
73 Acknowledgements 2017 MFMER slide-73
74 Questions?
75 2017 MFMER slide-75
76 Genetic hypercalciuria: pharmacologic treatments Thiazide diuretics Indapamide or chlorthalidone have longer half-lives and can be given once daily Be careful with dosing and close follow-up Potassium Citrate Citrate is a crystallization inhibitor Also can reduce urine calcium (? Effects on bone via neutralizing acid load)? Orthophosphate (K Phos neutral) Indirect effects on vitamin D and urine calcium Also a crystal growth inhibitor Large doses/ GI side effects/ no randomized trial 2017 MFMER slide-76
77 What disease is most likely? A. Primary Hyperoxaluria B. Enteric Hyperoxaluria C. Dent disease D. APRT deficiency E. Cystinuria 100% A MFMER slide-77
78 What diagnostic test would be most helpful? A. Urinalysis B. 24 hr urine oxalate C. Plasma oxalate D. Urine cystine E. Dual energy CT of the kidneys F. Urine retinol binding protein 100% A MFMER slide-78
79 Urine microscopy 2017 MFMER slide-79
80 What disease is most likely? A. Primary Hyperoxaluria B. Enteric Hyperoxaluria C. Dent disease D. APRT deficiency E. Cystinuria 100% A MFMER slide-80
81 What treatment would be most helpful? A. Potassium citrate B. Febuxostat C. Allopurinol D. Indapamide E. Very low protein diet F. Low sodium diet 100% A MFMER slide-81
82 APRT Deficiency 2017 MFMER slide-82
83 How would you interpret the elevated plasma oxalate? A. It is consistent with primary hyperoxaluria B. It is consistent with enteric hyperoxaluria C. It is consistent with excess dietary oxalate D. It is consistent with her reduced egfr (no oxalate issues) 100% A MFMER slide-83
84 What diagnostic test would now be helpful? A. Liver biopsy for enzyme analysis B. Genetic testing for alanine glyoxylate transferase (AGXT) mutations C. 72 hour fecal fat D. Spot urine for glycolate, glyoxylate, hydroxyoxoglutarate (HOG) 100% A MFMER slide-84
85 What diet measure would you stress? A. Low Salt B. High fluid intake C. Low protein D. These all help 100% A MFMER slide-85
86 What drug would you add on? A. Tiopronin B. D-penicillamine C. Potassium citrate D. Hydrochlorothaizide E. Febuxostat 100% A MFMER slide-86
87 Cystinuria: Current Solutions Increase solubility of cystine in urine Increase the ph of urine: CITRATE Decrease the concentration of cystine Increase the urine volume Decrease the amount of cystine excreted: REDUCE SALT, PROTEIN Change the cystine into cysteine Use cystine-binding thiols 2017 MFMER slide-87
88 Three forms of PH PH1 PH2 PH3 Enzyme AGT GR/HPR HOGA 1 Urine Glycolate Glycerate HOG % 74% 8% 8% Robijn S, KI 80:1146, MFMER slide-88
89 Cystine capacity (CysCap) and prediction of kidney stone events in cystinuria Modersitzki F, Harvey L, Assimos DG, Goldfarb DS ASN 2016 Cyscap+ patients had: higher UpH, higher V, lower Cys24, lower CysSS CysCap+ patients had significantly fewer stone events 2017 MFMER slide-89
90 Epidemiology Expected prevalence of the homozygous state is at least 1:50, , ,000 cases world wide cases in the US, cases in the UK cases in the Nordic Countires. Lack of awareness is likely, contributing to the low number of reported cases MFMER slide-90
RISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES Review of NASA s Evidence Reports on Human Health Risks
Mayo Clinic O Brien Urology Research Center RISK FACTORS AND TREATMENT STRATEGIES FOR URINARY STONES 2017 Review of NASA s Evidence Reports on Human Health Risks John C Lieske, MD July 27, 2017 What types
More informationThe Nuts and Bolts of Kidney Stones. Soha Zouwail Consultant Chemical Pathology UHW Renal Training Day 2019
The Nuts and Bolts of Kidney Stones Soha Zouwail Consultant Chemical Pathology UHW Renal Training Day 2019 Urinary Calculi Prevalence and incidence of kidney stones increasing across the world Environmental
More informationInborn errors of metabolism presenting with kidney stones: clinical aspects. Francesco Emma
Inborn errors of metabolism presenting with kidney stones: clinical aspects Francesco Emma Division of Nephrology and Dialysis Bambino Gesù Children s Hospital, IRCCS Rome, Italy September 6, 2016 Palazzo
More informationMedical Approach to Nephrolithiasis. Seth Goldberg, MD September 15, 2017 ACP Meeting
Medical Approach to Nephrolithiasis Seth Goldberg, MD September 15, 2017 ACP Meeting DISCLOSURES Seth Goldberg, MD Assistant Professor of Medicine Research support Abbott Kadmon Otsuka Pfizer Introduction
More informationNEPHROLITHIASIS Etiology, stone composition, medical management, and prevention
NEPHROLITHIASIS Etiology, stone composition, medical management, and prevention Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Epidemiology Prevalence 2-3%, maybe in
More information2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California
2015 OPSC Annual Convention syllabus February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California FRIDAY, FEBRUARY 6, 2015: 4:00pm - 5:00pm Stone Disease^ Presented by John Grimaldi, DO ^ California
More informationThis is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics
This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion
More informationSchool of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR
1 School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PLB SEMINAR URINARY (RENAL) STONE FORMATION An Overview What are Urinary (Renal)
More informationThis is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics
This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion
More informationMetabolic Stone Work-Up For Stone Prevention. Dr. Hazem Elmansy, MD, MSC, FRCSC Assistant Professor, NOSM, Urology Department
Metabolic Stone Work-Up For Stone Prevention Dr. Hazem Elmansy, MD, MSC, FRCSC Assistant Professor, NOSM, Urology Department Faculty/Presenter Disclosure Slide Faculty: Hazem Elmansy Relationships with
More informationIdentification and qualitative Analysis. of Renal Calculi
Identification and qualitative Analysis of Renal Calculi 1 -Renal Calculi: Kidney stones, renal calculi or renal lithiasis (stone formation) are small, hard deposits that form inside your kidneys. The
More informationA Rare Cause of Renal Stone Formation in Two Siblings. Chris Stockdale
A Rare Cause of Renal Stone Formation in Two Siblings Chris Stockdale Index case-patient A Born 2000 Parents (first cousins) from Indian sub-continent Paternal Grandmother received dialysis for ESRF Possible
More informationUrinary Calculus Disease. Urinary Stones: Simplified Metabolic Evaluation. Urinary Calculus Disease. Urinary Calculus Disease 2/8/2008
Urinary Stones: Simplified Metabolic Evaluation Marshall L. Stoller, M.D. Professor and Vice Chairman Department of Urology University of California San Francisco Incidence: 7-21/10,000 3 men: 1 woman
More informationMEDICAL STONE MANAGEMENT MADE EASY PRACTICAL ADVICE
MEDICAL STONE MANAGEMENT MADE EASY PRACTICAL ADVICE Comprehensive Kidney Stone Center at Duke University Medical Center Durham, North Carolina Glenn M. Preminger, M.D. UCLA State-of-the Art Urology 02
More informationUrolithiasis. Ali Kasraeian, MD, FACS Kasraeian Urology Advanced Laparoscopic, Robotic & Minimally Invasive Urologic Surgery
Urolithiasis Ali Kasraeian, MD, FACS Kasraeian Urology Advanced Laparoscopic, Robotic & Minimally Invasive Urologic Surgery Urolithiasis: Why should we care? Affects 5% of US men and women Men twice as
More informationPatient Results Report
Sample Physician MD Sample Practice 2250 W. Campbell Park Dr. Chicago, IL 60612 Current Test Overview SAMPLE ID RESULTS TURNAROUND (IN DAYS) PATIENT COLLECTION LAB RECEIPT TEST COMPLETION S000000 2 08/03/2005
More informationIntroduction to the primary hyperoxalurias Causes, Symptoms & Treatments. Prof. Dr. Bernd Hoppe
Introduction to the primary hyperoxalurias Causes, Symptoms & Treatments Prof. Dr. Bernd Hoppe Hyperoxaluria Underestimated as risk factor for calcium containing stones Most frequent risk factor in our
More informationManagement of common uroliths through diet
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Management of common uroliths through diet Author : Marge Chandler Categories : Canine, Companion animal, Feline, Vets Date
More informationGUIDELINES ON UROLITHIASIS
GUIDELINES ON UROLITHIASIS (Text updated May 2005) H.G. Tiselius (chairman), D. Ackermann, P. Alken, C. Buck, P. Conort, M. Gallucci, T. Knoll Eur Urol 2001;40:362-371 Introduction Urinary stone disease
More informationUrinary Calculus Disease
SYSTEMIC AND METABOLIC CONSIDERATION OF NEPHROLITHIASIS Marshall L. Stoller, M.D. Professor and Vice Chairman Department of Urology University of California San Francisco Urinary Calculus Disease Incidence:
More informationEQUILIBRIUM VERSUS SUPERSATURATED URINE HYPOTHESIS IN CALCIUM SALT UROLITHIASIS: A NEW THEORETICAL AND PRACTICAL APPROACH TO A CLINICAL PROBLEM
Scanning Microscopy Vol. 13, No. 2-3, 1999 (Pages 261-265) 0891-7035/99$5.00+.25 Scanning Microscopy International, Chicago Equilibrium (AMF O Hare), model for IL calcium 60666 USA salt urolithiasis EQUILIBRIUM
More informationClinical Biochemistry department/ College of medicine / AL-Mustansiriyah University
Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Dr. Ali al-bayati NUCLEOTIDE METABOLISM Lec. 3 The salvage pathway of purine synthesis Purines that result from the normal
More informationUrine Stone Screen requirements
Urine Stone Screen requirements Unique Identifying Index Number LP/PA/CB/CBSP030 Version number 4 Issue Date (this version) 03.08.15 Document Type Accreditation or Licensing Standard to which this applies
More informationEducational review: role of the pediatric nephrologists in the work-up and management of kidney stones
Pediatric Nephrology https://doi.org/10.1007/s00467-018-4179-9 EDUCATIONAL REVIEW Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones Carmen Inés Rodriguez
More informationTHIOLA (tiopronin) oral tablet
THIOLA (tiopronin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationMartin Konrad has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve.
Martin Konrad has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve. Nephrocalcinosis Clinical / Genetic Work-up and Outcome Martin Konrad University
More informationKidney Stone Update. Epidemiology of Kidney Stones. Lifetime Risk of Kidney Stone
Kidney Stone Update Michael Emmett MD Baylor University Medical Center Dallas, Texas Epidemiology of Kidney Stones Incidence About 0.3% Prevalence 10% Men 12% Women 8% Hospitalization Peak Age Stone Composition
More informationSAT24 Supersaturation Profile, 24 Hour, Urine
1-800-533-1710 SAT24 Supersaturation Profile, 24 Hour, Urine Patient ID Patient Name SAMPLEREPORT, SAT24 NORMAL Birth Date 1976-05-13 Gender M Age 40 Order Number Client Order Number Ordering Physician
More informationAssociation of serum biochemical metabolic panel with stone composition
bs_bs_banner International Journal of Urology (2015) 22, 195 199 doi: 10.1111/iju.12632 Original Article: Clinical Investigation Association of serum biochemical metabolic panel with stone composition
More informationSYSTEMIC IMPLICATIONS OF NEPHROLITHIASIS
SYSTEMIC IMPLICATIONS OF NEPHROLITHIASIS Marshall L. Stoller, M.D. Professor and Vice Chairman Department of Urology University of California San Francisco A STONE IS A STONE IS A STONE OR IS IT????? PATIENT
More informationGUIDELINES ON UROLITHIASIS
18 H.G. Tiselius (chairman), D. Ackermann, P. Alken, C. Buck, P. Conort, M. Gallucci Eur Urol 2001;40:362-371 Introduction Urinary stone disease continues to occupy an important place in everyday urological
More informationCombined Liver Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case Report
American Journal of Transplantation 2018; 18: 253 257 Wiley Periodicals Inc. Case Report 2017 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.14418
More informationApproach to the Patient with Nephrolithiasis; The Stone Quiz. Farahnak Assadi* 1, MD
Education Article Iran J Ped Sep 2007; Vol 17 (No 3), Pp:283-292 Approach to the Patient with Nephrolithiasis; The Stone Quiz Farahnak Assadi* 1, MD 1. Pediatric Nephrologist, Rush University Medical Center,
More informationNATIONAL KIDNEY MONTH
NATIONAL KIDNEY MONTH According to the WebMD website, kidneys have several specific roles: Maintain your body s balance of water and concentration of minerals, such as sodium, potassium, magnesium and
More informationUrologic Stone Disease. Urologic Stone Disease. Urologic Stone Disease. Urologic Stone Disease. Urologic Stone Disease 5/7/2010
Diagnosis and Treatment Stephen E. Strup MD William Farish Professor and Chief of Urology Director of Minimally Invasive Urologic Surgery University of Kentucky I will not cut, even for the stone, but
More informationShlomi Albert, M.D., Inc Warner Avenue, Suite 423 Fountain Valley, Ca Tel (714) Fax (714) Kidney Stone Disease in Adults
Shlomi Albert, M.D., Inc. 11160 Warner Avenue, Suite 423 Fountain Valley, Ca 92708 Tel (714)549-3333 Fax (714)549-3334 Kidney Stone Disease in Adults Overview Kidney stones are one of the most painful
More informationRenal Stones in Children
Renal Stones in Children Scottish Paediatric Renal & Urology Network Frank Willis Renal Unit RHSC-Yorkhill Glasgow May 2009 Aetiology Differs from adults Varies with geography & over time Most have primary
More informationWelcome to the UK Primary Hyperoxaluria family support day
Welcome to the UK Primary Hyperoxaluria family support day Understanding Primary Hyperoxaluria (PH) / Oxalosis together Dr Sally-Anne Hulton Kim Hollander % PH Patients PH is diagnosed at any age 50 45
More informationEffective Health Care Program
Comparative Effectiveness Review Number 61 Effective Health Care Program Recurrent Nephrolithiasis in Adults: Comparative Effectiveness of Preventive Medical Strategies Executive Summary Introduction Nephrolithiasis
More informationNutritional Management of Kidney Stones (Nephrolithiasis)
Nutritional Management of Kidney Stones (Nephrolithiasis) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published
More informationKidney Stones EDITING FILE. Biochemistry Team 437 "الل ھ م لا س ھ ل إ لا ما ج ع ل ت ھ س ھ لا وأن ت ت ج ع ل الح ز ن إذ ا ش ي ت س ھ لا " Renal block
"الل ھ م لا س ھ ل إ لا ما ج ع ل ت ھ س ھ لا وأن ت ت ج ع ل الح ز ن إذ ا ش ي ت س ھ لا " Kidney Stones Biochemistry Team 437 Color index: Doctors slides Doctor s notes Extra information Highlights Renal block
More informationHereditary Kidney Stones
In: Urolithiasis ISBN: 978-1-63463-500-4 Editor: Joseph Fletcher 2015 Nova Science Publishers, Inc. The exclusive license for this PDF is limited to personal website use only. No part of this digital document
More informationLessons Learned from Endoscopy
Mayo Clinic O Brien Urology Research Center Lessons Learned from Endoscopy August 22, 2015 Amy Krambeck, MD Mayo Clinic Department of Urology John C. Lieske, MD Fang Zhao, MD Mayo Clinic Division of Nephrology
More informationIntroduction to Clinical Diagnosis Nephrology
Introduction to Clinical Diagnosis Nephrology I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of Florida College
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationOxalate (urine, plasma)
Oxalate (urine, plasma) 1 Name and description of analyte 1.1 Name of analyte Oxalate 1.2 Alternative names 1.3 NLMC code To follow 1.4. Function of analyte Oxalate is a metabolic end product primarily
More informationA Phase 1/2 Trial of Lumasiran (ALN-GO1), an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1
A Phase 1/2 Trial of Lumasiran (ALN-GO1), an Investigational RNAi Therapeutic for Primary Hyperoxaluria Type 1 OxalEurope Meeting Naples, Italy 8 June 2018 2018 Alnylam Pharmaceuticals, Inc. Background
More informationEvaluation of the Recurrent Stone Former
Urol Clin N Am 34 (2007) 315 322 Evaluation of the Recurrent Stone Former Paramjit S. Chandhoke, MD, PhD* Department of Urology, Northwest Permanente, Portland, OR, USA At one time, metabolic kidney stone
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationDietary Management of Nephrolithiasis. Sarah Yttri, NP Duke University Duke Comprehensive Kidney Stone Center
Dietary Management of Nephrolithiasis Sarah Yttri, NP Duke University Duke Comprehensive Kidney Stone Center None Disclosures Prevalence 1 in 11 individuals in the US 10.6% of men, 7.1% of women 70% increase
More informationDiet and fluid prescription in stone disease
http://www.kidney-international.org & 2006 International Society of Nephrology mini review Diet and fluid prescription in stone disease EN Taylor 1 and GC Curhan 1,2 1 Renal Division, Department of Medicine,
More informationPart I: On-line web-based survey of Dalmatian owners GENERAL INFORMATION
Dr. Bartges' final report on the Dal stone survey: Commissioned by the Dalmatian Club of America Foundation (DCAF) Published in the DCA magazine, The Spotter, Summer 2006 Part I: On-line web-based survey
More informationNew aspects of acid-base disorders
New aspects of acid-base disorders I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Division of Nephrology, Hypertension and Transplantation University of Florida College of Medicine
More informationPrimary Hyperoxaluria/ Oxalosis
Primary Hyperoxaluria/ Oxalosis Annual Dialysis Conference, Seattle, WA, Feb 28, 2016 Eileen D. Brewer, MD Professor of Pediatrics Pediatric Renal Section Aims Review clinical presentation, causes and
More informationThe 82 nd UWI/BAMP CME Conference November 18, Jeetu Nebhnani MBBS D.M. Urology Consultant Urologist
The 82 nd UWI/BAMP CME Conference November 18, 2017 Jeetu Nebhnani MBBS D.M. Urology Consultant Urologist Disclosures Outline Index case Introduction Etiology Risk factors Acute stone event Conservative
More informationSTONES Dietary and Medical Therapy Prevention Adjuvant. Manoj Monga, MD The Cleveland Clinic
STONES Dietary and Medical Therapy Prevention Adjuvant Manoj Monga, MD The Cleveland Clinic Incidence and Prevalence Worldwide, 1 in 10 people experience a kidney stone in their lifetime Recurrence rates
More informationA Prospective Study of Risk Factors for Nephrolithiasis After Roux-en-Y Gastric Bypass Surgery
A Prospective Study of Risk Factors for Nephrolithiasis After Roux-en-Y Gastric Bypass Surgery Alyssa M. Park,* Douglas W. Storm, Brant R. Fulmer, Christopher D. Still, G. Craig Wood and James E. Hartle,
More informationRenal calculi formation and
Renal calculi formation and treatment : New insights David A. Lifshitz, M.D. Director of Minimally Invasive Urology Rabin Medical Center and Tel Aviv University School of Medicine, Israel Where is Israel
More informationLaboratory diagnosis of Primary hyperoxaluria. Dr Gill Rumsby UCL Hospitals London, UK
Laboratory diagnosis of Primary hyperoxaluria Dr Gill Rumsby UCL Hospitals London, UK Steps involved in diagnosis Metabolite Enzyme (protein) Gene (DNA) Tissue/body fluid needed for analysis Metabolite
More informationNephrolithiasis cases
Nephrolithiasis cases Primary Care Internal Medicine October 2015 Brian Eisner MD Co-director, Kidney Stone Program Massachusetts General Hospital, Harvard Medical School CASE 1 45 year old male, otherwise
More informationuric acid Non electrolytes of the plasma
73 uric acid Non electrolytes of the plasma 1 Purines and uric acid Fig 2 JFI Uric acid is the major product of catabolism of the purine nucleosides adenosine and guanosine, Uric acid is sparingly soluble
More informationGuideline of guidelines: kidney stones
Justin B. Ziemba and Brian R. Matlaga* Division of Urology, Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, and *James Buchanan Brady Urological
More informationExcretory System. Biology 2201
Excretory System Biology 2201 Excretory System How does the excretory system maintain homeostasis? It regulates: Body heat Water-salt concentrations Acid-base concentrations Metabolite concentrations ORGANS
More informationExcretory System. Excretory System
Excretory System Biology 2201 Excretory System How does the excretory system maintain homeostasis? It regulates: Body heat Water-salt concentrations Acid-base concentrations Metabolite concentrations 1
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationKidney Stones in Children
Kidney Stones in Children National Kidney and Urologic Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is a kidney stone? A kidney stone
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Effect of Diet Orange soda on urinary lithogenicity Permalink https://escholarship.org/uc/item/27x8w1h4 Journal Urological Research, 40(3)
More informationQuaseem et coll. Ann Intern Med 2014
Dietary and Pharmacologic Management to prevent Recurrent Nephrolithiasis in Adults A Clinical Practice Guideline From the American College of Physicians Introduction Approximately 80% of adults with kidney
More informationUrinary Stones: Key Points
Urinary Stones: Key Points Don Griffith, MD Professor, Baylor; Dept of Urology Micheal E DeBakey VAMC, Houston USNR Flight Surgeon CVA-66 USS America Vietnam Era Both Stones are CaOx 1H20 Why Difference?
More informationFredric L. Coe,, Andrew Evan, Elaine Worcester
Kidney stone disease Fredric L. Coe,, Andrew Evan, Elaine Worcester J Clin Invest. 2005;115(10):2598-2608. https://doi.org/10.1172/jci26662. Science in Medicine About 5% of American women and 12% of men
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationChronic Kidney Disease. Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital
Chronic Kidney Disease Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital Health Seminar Series Date 12 May 2013 Objectives Normal functioning of Kidneys. Risk factors to
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationNephrology - the study of the kidney. Urology - branch of medicine dealing with the male and female urinary systems and the male reproductive system
Urinary System Nephrology - the study of the kidney Urology - branch of medicine dealing with the male and female urinary systems and the male reproductive system Functions of the Urinary System 1. Regulation
More informationCorrespondence between stone composition and urine supersaturation in nephrolithiasis
Kidney International, Vol. 51 (1997), pp. 894 900 Correspondence between stone composition and urine supersaturation in nephrolithiasis JOAN H. PARKS, MARK COWARD, and REDRIC L. COE Program in Nephrology,
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAlterations of Renal and Urinary Tract Function
Alterations of Renal and Urinary Tract Function Chapter 29 Urinary Tract Obstruction Urinary tract obstruction is an interference with the flow of urine at any site along the urinary tract The obstruction
More informationChapter 23. Composition and Properties of Urine
Chapter 23 Composition and Properties of Urine Composition and Properties of Urine (1 of 2) urinalysis the examination of the physical and chemical properties of urine appearance - clear, almost colorless
More informationChapter 20 Diseases of the kidney:
Chapter 20 Diseases of the kidney: 1. Which of the following is seen in Nephrotic syndrome (2000, 2004) (a) Albumin is lost in the urine, while other globulins are unaffected (b) Early hypertension (c)
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDietary and medical management of recurrent nephrolithiasis
REVIEW EDUCATIONAL OBJECTIVE: Readers will apply interventions to reduce the risk of recurrent nephrolithiasis SILVI SHAH, MD Department of Nephrology, University of Alabama at Birmingham JUAN CAMILO CALLE,
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationNon-protein nitrogenous substances (NPN)
Non-protein nitrogenous substances (NPN) A simple, inexpensive screening test a routine urinalysis is often the first test conducted if kidney problems are suspected. A small, randomly collected urine
More informationTherapeutics of Diuretics
(Last Updated: 08/22/2018) Created by: Socco, Samantha Therapeutics of Diuretics Thambi, M. (2017). The Clinical Use of Diuretics. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago.
More informationPHYSICAL CHARACTERISTICS, QUALITATIVE AND QUANTITATIVE ANALYSIS OF URINARY STONES (PATHARI)
Int. J. Chem. Sci.: 11(1), 2013, 457463 ISSN 0972768X www.sadgurupublications.com PHYSICAL CHARACTERISTICS, QUALITATIVE AND QUANTITATIVE ANALYSIS OF URINARY STONES (PATHARI) SUMAN PARIHAR a, PRASOON HADA
More informationDiet for Kidney Stone Prevention
Diet for Kidney Stone Prevention National Kidney and Urologic Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH How does diet affect the risk
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationEURACARE Multi-Specialist Hospital
EURACARE Multi-Specialist Hospital PATIENT INFORMATION FORM MEDICAL MANAGEMENT OF URINARY STONE DISEASE Kidney & Urinary Stones Kidney stones, one of the most painful of the urologic disorders, have beset
More informationAllen Rodgers 1, Daniel Gauvin 2, Samuel Edeh 2, Shameez Allie-Hamdulay 1, Graham Jackson 1, John C. Lieske 2,3 * Abstract.
Sulfate but Not Thiosulfate Reduces Calculated and Measured Urinary Ionized Calcium and Supersaturation: Implications for the Treatment of Calcium Renal Stones Allen Rodgers 1, Daniel Gauvin 2, Samuel
More informationKeeping your kidneys young
Keeping your kidneys young Ramy M. Hanna MD FASN FACP Clinical Instructor David Geffen School of Medicine UCLA Health Department of Medicine Division of Nephrology June 25, 2018 The kidneys gets a lot
More information